drugset / Trial / NCT00121771
Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men
Phase 1
Completed
32 enrolled
London School of Hygiene and Tropical Medicine
Medical Research Council · collabUniversity of Oxford · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Animal and human studies have shown that the prime-boost immunization strategy using malaria antigens expressed in plasmid or viral vectors induces strong cellular immune responses. An immunization regimen with the malaria vaccines DNA ME-TRAP followed by MVA ME-TRAP induced strong T cell responses in adults in the United Kingdom (UK) and in the Gambia but did not provide significant clinical protection against infection. The investigators assessed two new vaccines which utilize a similar immunization strategy but a different malaria antigen, a circumsporozoite (CS) protein. The entire CS protein was expressed either in a modified vaccinia virus Ankara (MVA) CS, or an attenuated fowlpox virus strain (FP9) CS.
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- 2004-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FP9 CS | Unknown | 5e+07 unknown | Other |
| Subject | FP9 CS | Unknown | 1e+08 unknown | Other |
| Subject | MVA CS | Vaccine | 5e+07 unknown | Other |
| Subject | MVA CS | Vaccine | 1e+08 unknown | Other |